1. Home
  2. RGNT vs AYTU Comparison

RGNT vs AYTU Comparison

Compare RGNT & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RGNT

Regentis Biomaterials Ltd. Ordinary Shares

N/A

Current Price

$2.20

Market Cap

24.6M

Sector

Health Care

ML Signal

N/A

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.17

Market Cap

27.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGNT
AYTU
Founded
2004
N/A
Country
Israel
United States
Employees
8
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.6M
27.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
RGNT
AYTU
Price
$2.20
$2.17
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
677.4K
25.1K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$27,632,080.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
277.47
52 Week Low
$1.23
$1.65
52 Week High
$15.50
$3.07

Technical Indicators

Market Signals
Indicator
RGNT
AYTU
Relative Strength Index (RSI) 40.11 46.15
Support Level $1.82 $2.11
Resistance Level $3.35 $2.31
Average True Range (ATR) 0.45 0.07
MACD -0.26 0.00
Stochastic Oscillator 2.74 28.32

Price Performance

Historical Comparison
RGNT
AYTU

About RGNT Regentis Biomaterials Ltd. Ordinary Shares

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: